Fidanci, Inang D.Kavakli, KaanUcar, CananTimur, CetinMeral, AdaletKilinc, YurdanurSayilang, Huelya2020-03-262020-03-2620080957-52351473-5733https://dx.doi.org/10.1097/MBC.0b013e3282f9b193https://hdl.handle.net/20.500.12395/22410Factor VIII (FVIII) replacement therapy is ineffective in hemophilia A patients who develop alloantibodies (inhibitors) against FVIII. The type of factor 8 (F8) gene mutation, genes in the major histocompatibility complex loci, and also polymorphisms in IL-10 and tumor necrosis factor-alpha are the major predisposing factors for inhibitor formation. The present study was initiated to reveal the F8 gene mutation profile of 30 severely affected high-responder patients with inhibitor levels of more than 5 Bethesda U (BU)/ml and four low-responder patients with inhibitors less than 5 BU/ml. Southern blot and PCR analysis were performed to detect intron 22 and intron 1 inversions, respectively. Point mutations were screened by DNA sequence analysis of all coding regions, intron/exon boundaries, promoter and 3' UTR regions of the F8 gene. The prevalent mutation was the intron 22 inversion among the high-responder patients followed by large deletions, small deletions, and nonsense mutations. Only one missense and one splicing error mutation was seen. Among the low-responder patients, three single nucleotide deletions and one intron 22 inversion were found. All mutation types detected were in agreement with the severe hemophilia A phenotype, most likely leading to a deficiency of and predisposition to the development of alloantibodies against FVIII. It is seen that Turkish hemophilia A patients with major molecular defects have a higher possibility of developing inhibitors.en10.1097/MBC.0b013e3282f9b193info:eu-repo/semantics/closedAccessfactor 8 gene mutationhemophilia Ainhibitors against Factor VIIIArticle19538338818600086Q3WOS:000257927600008Q4